if the site is at the level of the esophagogastric junction, a laparotomy is preferable, and the stomach can be used to reinforce the repair. If the damage to the esophagus is too extensive to ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut. Ongoing ...

Patients who had esophageal or gastric cancer, previous esophageal ... Four biopsy specimens were obtained from the squamocolumnar junction, with one cup of the biopsy forceps positioned on ...

Thoracoabdominal esophagectomy was performed for esophageal tumors and for esophagogastric junction tumors extending ... the construction and pull-up of a gastric conduit. Regional lymphadenectomy ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. | Merck & Co. and Eisai have to deal with ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

ALX Oncology Holdings Inc. ( ALXO, Financials) saw its stock price fall 15.8% to $1.52 as of 2:32 p.m. GMT-5 on Thursday, despite announcing positive updated results from its ASPEN-06 Phase 2 clinical ...